Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group

References

• Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151–1160.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. diagnosis and management. Am J Clin Dermatol. 2001;2:159–165.
   PubMedGoogle Scholar
• Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. 2009. Available from http://www.dermatology.ca/psoriasisguidelines.
   Google Scholar
• Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60:962–971.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–174.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke W-H, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3- - Guidelines on the treatment of psoriasis vulgaris. update. J Dtsch Dermatol Ges. 2012;10:S1–S95.
   Web of Science ®Google Scholar
• Ortonne JP, Chimenti S, Luger T, Puig L, Reid F, Trüeb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23:1435–1444.
   PubMed Web of Science ®Google Scholar
• Raboobee N, Aboobaker J, Jordaan HF, Sinclair W, Smith JM, Todd G, et al. Guideline on the management of psoriasis in South Africa. S Afr Med J. 2010;100:257–282.
   PubMedGoogle Scholar
• Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102.
   PubMed Web of Science ®Google Scholar
• Dermatological Society of Malaysia. Consensus statement: the management of psoriasis. 1996.
   Google Scholar
• Philippine Dermatological Society. Guidelines of care for psoriasis. 2002.
   Google Scholar
• Taiwanese Dermatological Association. Treatment guideline for psoriasis: Taiwan. In MIMS dermatology. Taiwan: UBM Medica, 2011/2012.
   Google Scholar
• Loo SK. Psoriasis. care, health, arthritic management. 2012. 1–16. Available from http://www.hkarf.org/Eng/doc/charm07.pdf.
   Google Scholar
• Warren RB, Brown BC, Griffiths CE. Topical treatments for scalp psoriasis. Drugs. 2008;68:2293–2302.
   PubMedGoogle Scholar
• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535–546.
   PubMed Web of Science ®Google Scholar
• Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol. 2011;65:870–873.
   PubMed Web of Science ®Google Scholar
• Chang Y-T, Chen T-Z, Liu P-C, Chen Y-C, Chen Y-J, Huang Y-L, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009;89:262–266.
   PubMedGoogle Scholar
• Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol. 1984;10:965–968.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63:40–46.
   PubMed Web of Science ®Google Scholar
• Chen HH, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatol Sinica. 2003;21:216–224.
   Google Scholar
• Siow KY, Safdar NA, Chong KH, Chua KB. A clinical appraisal of patients with psoriasis treated in Seremban General Hospital, Malaysia. Med J Malaysia. 2004;59:330–334.
   PubMedGoogle Scholar
• Chang CC, Gangaram HB, Hussein SH. Malaysian Psoriasis Registry–preliminary report of a pilot study using a newly revised registry form. Med J Malaysia. 2008;63:68–71.
   PubMedGoogle Scholar
• van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197:326–334.
   PubMed Web of Science ®Google Scholar
• Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510–518.
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall L. Childhood psoriasis. Cutis. 1999;64:309–314.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lin Y, Liu HJ, Huang CZ, Feng AP, Li JW. Childhood psoriasis: a study of 137 cases from central China. World J Pediatr. 2010;6:260–264.
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Crowson CS, McEvoy MT, Dremers HM. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62:979–987.
   PubMed Web of Science ®Google Scholar
• Nanda A, Al-Fouzan AS, El-Kashlan M, Al-Sweih N, Al-Muzairai I. Salient features and HLA markers of childhood psoriasis in Kuwait. Clin Exp Dermatol. 2000;25:147–151.
   PubMedGoogle Scholar
• Fan X, Yang S, Sun LD, Liang YH, Gao M, Zhang KY, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol. 2007;87:335–340.
   PubMedGoogle Scholar
• Tsai TF, Hu CY, Tsai WL, Chu CY, Lin SJ, Liaw SH, et al. HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Arch Dermatol Res. 2002;294:214–220.
   PubMedGoogle Scholar
• Chiu HY, Huang PY, Jee SH, Hu CY, Chou CT, Chang YT, et al. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol. 2012;166:288–297.
   PubMed Web of Science ®Google Scholar
• de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140–147.
   PubMed Web of Science ®Google Scholar
• Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9:131–135.
   PubMed Web of Science ®Google Scholar
• Yang Y, Koh D, Khoo L, Nyunt SZ, Ng V, Goh CL. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. Int J Dermatol. 2005;44:925–929.
   PubMed Web of Science ®Google Scholar
• Lin TY, See LC, Shen YM, Liang CY, Chang HN, Lin YK. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. 2011;34:186–196.
   PubMedGoogle Scholar
• Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25:606–615.
   PubMed Web of Science ®Google Scholar
• Prohic A. Identification of Malassezia species isolated from scalp skin of patients with psoriasis and healthy subjects. Acta Dermatovenerol Croat. 2003;11:10–16.
   PubMedGoogle Scholar
• Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004;51:785–798.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203:153–156.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64:ii65–ii68; discussion ii69–ii73.
   PubMed Web of Science ®Google Scholar
• Farhi DB, Falissard B, Dupuy A. Global assessment of psoriasis severity and change from photographs: a valid and consistent method. J Invest Dermatol. 2008;128:2198–2203.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther. 1998;23:391–398.
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
   PubMed Web of Science ®Google Scholar
• Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138:803–807.
   PubMed Web of Science ®Google Scholar
• De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002;138:1221–1227; discussion 1227.
   PubMedGoogle Scholar
• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18–ii23; discussion ii24–ii25.
   PubMed Web of Science ®Google Scholar
• Crowley J. Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol. 2010;9:912–918.
   PubMed Web of Science ®Google Scholar
• Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;2:CD005028.
   Google Scholar
• Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217:107–113.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59:455–463.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161:159–166.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160:170–176.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Ganslandt C, Tan J, Nordin P, Kragballe K, Segaert S. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol. 2009;23:919–926.
   PubMed Web of Science ®Google Scholar
• Luger TA, Cambazard F, Larsen FG, Bourcier M, Gupta G, Clonier F, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217:321–328.
   PubMed Web of Science ®Google Scholar
• Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai. 2007;90:1997–2002.
   PubMedGoogle Scholar
• Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat. 2006;17:90–95.
   PubMed Web of Science ®Google Scholar
• Kragballe K. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails. Curr Probl Dermatol. 2009;38:160–171.
   PubMedGoogle Scholar
• Tsuji G, Takahara M, Uchi H, Matsuda T, Chiba T, Takeuchi S, et al. Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes: the basis of its anti-inflammatory effect. J Invest Dermatol. 2012;132:59–68.
   PubMed Web of Science ®Google Scholar
• Barrett C, Lowson D, Blades KJ. Limited benefit of combined use of tar-based shampoo with 50 microg/ml calcipotriol solution in scalp psoriasis. J Dermatolog Treat. 2005;16:175.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Yeh TY. The use of biologics for psoriasis in Asia-Pacific region. Curr Rheumatol Rev. 2009;5:149–152.
   Google Scholar
• Gattu S, Rashid RM Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2009;23:36–41.
   PubMedGoogle Scholar
• Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59:27–33.
   PubMed Web of Science ®Google Scholar
• Ersser SJ, Cowdell FC, Latter SM, Healy E. Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol. 2010;163:1044–1049.
   PubMed Web of Science ®Google Scholar
• Ersser SJ, Surridge H, Wiles A. What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract. 2002;8:367–376.
   PubMed Web of Science ®Google Scholar
• Housman TS, Mellen BG, Rapp SR, Fleischer AB, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327–332.
   PubMed Web of Science ®Google Scholar
• Kircik L. The evolving role of therapeutic shampoos for targeting symptoms of inflammatory scalp disorders. J Drugs Dermatol. 2010;9:41–48.
   PubMedGoogle Scholar
• Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008;26:424–431.
   PubMed Web of Science ®Google Scholar